240 citations,
April 2011 in “Pigment Cell & Melanoma Research” Melanocyte stem cells in hair follicles are key for hair color and could help treat greying and pigment disorders.
39 citations,
May 2010 in “Stem Cells” Ephrins slow down skin and hair follicle cell growth.
23 citations,
June 2012 in “Molecular Biology Reports” VEGF stimulates hair cell growth and increases growth receptor levels through a specific signaling pathway.
4 citations,
March 2012 in “Annals of oncology” New treatment with green tea polyphenols and nicotinamide improves skin problems from cancer therapy.
3 citations,
October 2018 in “Archives of Dermatological Research” Applying InlB321/15 to wounds sped up healing in mice.
1 citations,
June 2023 in “Advances in therapy” Ripretinib is effective and safe for treating advanced GIST in Chinese patients, particularly for non-gastric GISTs.
1 citations,
February 2015 in “Clinical and Experimental Dermatology” A man got six skin cancers within a year after a cell transplant for leukemia but was cancer-free 32 months later; skin checks are important post-transplant.
November 2013 in “John Wiley & Sons, Ltd eBooks” Skin symptoms can indicate endocrine disorders and have various treatments.
15 citations,
July 2008 in “Journal of Dermatological Science” Ephrin-A3 helps increase and speed up hair growth in baby mice.
8 citations,
May 2017 in “Singapore Medical Journal” A Korean woman with complete hair loss regrew her hair after taking tofacitinib, with no side effects.
3 citations,
April 2016 in “Journal of Investigative Dermatology” Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.
1 citations,
January 2014 in “Elsevier eBooks” Melanocytes produce melanin; their defects cause vitiligo and hair graying, with treatments available for vitiligo.
520 citations,
February 2001 in “Journal of Clinical Investigation” VEGF helps hair grow and determines follicle size by increasing blood vessel growth.
222 citations,
October 2014 in “Annual Review of Pharmacology and Toxicology” Eph receptors and ephrins may be promising targets for treating diseases, but more understanding is needed for effective and safe therapies.
192 citations,
January 2015 in “Journal of the American Academy of Dermatology” Targeted cancer therapies often cause serious skin problems that need careful management.
179 citations,
October 2018 in “American Journal of Clinical Dermatology” Cancer treatments targeting specific cells and the immune system can cause skin, mouth, hair, and nail problems, affecting patients' quality of life and treatment adherence.
159 citations,
October 2015 in “Science Advances” Blocking JAK-STAT signaling can lead to hair growth.
138 citations,
February 2007 in “European journal of cancer” EGFR inhibitors often cause skin problems and other side effects, but these are usually reversible and can be managed to keep patients comfortable.
119 citations,
November 2014 in “Trends in Cell Biology” Fibroblast growth factor receptor signaling controls cell development and repair, and its malfunction can cause disorders and cancer, but it also offers potential for targeted therapies.
101 citations,
January 1997 in “Journal of Investigative Dermatology Symposium Proceedings” Nerves and chemicals in the body can affect hair growth and loss.
73 citations,
September 2003 in “Journal of Pharmacology and Experimental Therapeutics” Hair color loss can indicate the effectiveness of a drug targeting the KIT protein in mice and humans.
64 citations,
March 2005 in “Journal of Investigative Dermatology” Brain-Derived Neurotrophic Factor (BDNF) slows down hair growth and promotes hair follicle regression.
47 citations,
May 1995 in “Journal of Investigative Dermatology” Hair follicles in people with alopecia have lower levels of a key blood vessel growth protein.
44 citations,
September 2015 in “Annals of Oncology” Targeted cancer therapies have a significant but lower risk of causing hair loss compared to chemotherapy.
44 citations,
April 2006 in “Expert opinion on drug safety” Gefitinib can cause skin problems, diarrhea, and nausea, but rarely causes severe lung disease or hair loss.
42 citations,
April 2012 in “Seminars in Oncology” Targeted cancer therapies often cause skin problems that need careful management to improve patient quality of life and treatment success.
42 citations,
October 2011 in “Seminars in Cell & Developmental Biology” Eph/ephrin signaling is important for skin cell behavior and could be targeted to treat skin diseases.
38 citations,
February 2012 in “Supportive Care in Cancer” Skin problems like acne, dry skin, and nail and hair changes are common in patients taking EGFR inhibitors.
32 citations,
December 2018 in “Cytokine” Type I interferons play a key role in the development of various skin diseases.
32 citations,
January 2012 in “International Journal of Dermatology” Skin side effects from EGFR inhibitor cancer treatment can be managed effectively, often without stopping the medication.